ACE and Alzheimer disease: To test whether diminished acetylcholine neurotransmission is responsible for the aging-associated increase in LIE, we examined the Acec00215/+ flies with the heterozygous mutation in acetylcholinesterase (Ace; EC 3.1.1.7) that breaks down acetylcholine and is a target for the first line medication to treat Alzheimer’s disease.